Evidence map›Paper›PMID 42282066›Full record

ArticleEuropean heart journal open2026

Baseline characteristics of patients enrolled in the AZIMUTH trial: an e-health-integrated, smartphone app-based model of care for heart failure patients.

Domenico D'Amario, Donato Antonio Paglianiti, Renzo Laborante, Stefano Elia, Gaetano Rizzo, Simona Giubilato, Maria Catalano, Francesco Amico, Maurizio Volterrani, Attilio Restivo and 17 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in European heart journal open, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

27 authors.

Domenico D'AmarioDepartment of Translational Medicine, University of Eastern Piedmont, Via Solaroli 17, Novara 28100, Italy.ORCID https://orcid.org/0000-0003-3774-8330
Donato Antonio PaglianitiDepartment of Translational Medicine, University of Eastern Piedmont, Via Solaroli 17, Novara 28100, Italy.ORCID https://orcid.org/0000-0003-2556-4809
Renzo LaboranteDepartment of Clinical Science and Education, Södersjukhuset, Karolinska Institutet, Sjukhusbacken 10, Stockholm, Sweden.
Stefano EliaDepartment of Translational Medicine, University of Eastern Piedmont, Via Solaroli 17, Novara 28100, Italy.
Gaetano RizzoDepartment of Translational Medicine, University of Eastern Piedmont, Via Solaroli 17, Novara 28100, Italy.
Simona GiubilatoDepartment of Cardiology, Cannizzaro Hospital, Via Messina 829, Catania, Italy.
Maria CatalanoDepartment of Cardiology, Cannizzaro Hospital, Via Messina 829, Catania, Italy.
Francesco AmicoDepartment of Cardiology, Cannizzaro Hospital, Via Messina 829, Catania, Italy.
Maurizio VolterraniDepartment of Cardiopulmonary, IRCCS San Raffaele Roma, Via della Pisana 235, Rome 00166, Italy.ORCID https://orcid.org/0000-0002-2624-9213
Attilio RestivoCatholic University of the Sacred Heart, Largo F. Vito 1, 00168, Rome, Italy.ORCID https://orcid.org/0000-0002-9097-5287
Stefano PatarnelloFondazione Universitaria Policlinico A. Gemelli IRCCS, Largo. A. Gemelli 8, 00168, Rome, Italy.
Sofoklis KyriazakosInnovation Sprint Srl, Brussels, Clos Chapelle-aux-Champs 30, Bruxelles, Belgium.
Alice LuraschiFondazione Universitaria Policlinico A. Gemelli IRCCS, Largo. A. Gemelli 8, 00168, Rome, Italy.
Agni DelviniotiFondazione Universitaria Policlinico A. Gemelli IRCCS, Largo. A. Gemelli 8, 00168, Rome, Italy.
Federica TomassiniFondazione Universitaria Policlinico A. Gemelli IRCCS, Largo. A. Gemelli 8, 00168, Rome, Italy.
Konstantina KostopoulouInnovation Sprint Srl, Brussels, Clos Chapelle-aux-Champs 30, Bruxelles, Belgium.
Antonio IaconelliCatholic University of the Sacred Heart, Largo F. Vito 1, 00168, Rome, Italy.ORCID https://orcid.org/0000-0001-7413-8449
Enrico IncaminatoDepartment of Translational Medicine, University of Eastern Piedmont, Via Solaroli 17, Novara 28100, Italy.
Francesco CanonicoThoraco-Cardio-Vascular Department, Azienda Ospedaliero-Universitaria Maggiore Della Carità, Viale Mazzini 18, Novara 28100, Italy.
Marco GoriniHealthcare Innovation, AstraZeneca, V.le Decumano 39, 20157, Rho, Italy.
Stefania MarcoliHealthcare Innovation, AstraZeneca, V.le Decumano 39, 20157, Rho, Italy.
Vincenzo BartoliHealthcare Innovation, AstraZeneca, V.le Decumano 39, 20157, Rho, Italy.
Thomas GriffithsHealthcare Service Design, AstraZeneca, Pancras Sq, London, UK.
Peter FeniciCatholic University of the Sacred Heart, Largo F. Vito 1, 00168, Rome, Italy.
Alfredo CesarioCatholic University of the Sacred Heart, Largo F. Vito 1, 00168, Rome, Italy.
Giuseppe PattiDepartment of Translational Medicine, University of Eastern Piedmont, Via Solaroli 17, Novara 28100, Italy.ORCID https://orcid.org/0000-0002-5404-3968
Filippo CreaCatholic University of the Sacred Heart, Largo F. Vito 1, 00168, Rome, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Aims: The 'FondAZione A. Gemelli IRCCS Artificial Intelligence Empowered Digital PlatforM to sUpport paTients with Heart Failure' (AZIMUTH) study is a multicentre prospective outpatient trial assessing an app-based, e-health-integrated model of care for heart failure (HF) patients. Its primary aim is to evaluate the feasibility and patient/provider acceptance of the app-based intervention, while key secondary aims include assessing its clinical impact through changes in guideline-directed medical therapy (GDMT) prescription/adherence and quality of life. Methods and results: Feasibility is defined as ≥70% of participants maintaining active engagement with the app during follow-up. The platform integrates patient-reported symptoms, connected measurements, medication reminders, and two-way messaging, with clinician review of alerts and trends. Between December 2021 and January 2024, 300 adults with chronic HF, irrespective of left ventricular ejection fraction (LVEF), were enrolled across four Italian centres. Median age was 66 years (IQR 59-73), 78.3% were male, and 82.3% were NYHA Class I-II. LVEF distribution was balanced (HFrEF 35.3%, HFmrEF 25.7%, HFpEF 38.7%). Comorbidities were frequent: hypertension 81.3%, dyslipidaemia 75.7%, ischaemic heart disease 41.0%, diabetes 29.7%, atrial fibrillation 29.7%, and chronic kidney disease 21.7%. At enrolment, RASi/ARNI were prescribed in 69.6%, beta-blockers in 76.9%, MRAs in 16.1%, and SGLT2i in 23.7%. Compared with HFrEF-focused trials, uptake of foundational classes was lower, consistent with the broader LVEF spectrum and real-world constraints. Conclusion: The AZIMUTH cohort represents a contemporary, heterogeneous HF population with variable and suboptimal GDMT uptake. Digital health interventions have the potential to optimize care delivery and increase adherence in real-world settings.

Indexed as

Digital healthGuideline-directed medical therapyHeart failureRemote monitoring

Identifiers

PMID42282066
PMCPMC13252453

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.